ImmuNext Inc Profile last edited on: 5/27/2020
CAGE: 6BYC6
UEI: SBSALV1MKHA3
Business Identifier: Novel immunotherapies for autoimmune disease and cancer 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Grafton
Congr. District: 02
County: Grafton
Public Profile
With core competencies in discovery, target biology and pre-clinical drug development, ImmuNext is organized around development of immunomodulatory compounds designed to modulate the immune system to treat cancer and autoimmune diseases. Negative checkpoint regulators are changing the way cancer is treated. ImmuNext's lead product, anti-VISTA, is partnered with Janssen for the treatment of cancer. A second product, VISTA agonists, is partnered with Hoffmann-La Roche for the treatment of autoimmune diseases. Other programs include a CD40 agonist for neoantigen cancer vaccines and a novel immuno-metabolic target, in each case establishing new classes of compounds. ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. The immunoregulatory molecule, CD40L, is critical to the progression of a wide spectrum of autoimmune diseases. Antibodies that block the function of CD40L have proven in pre-clinical models of autoimmunity to be effective agents in treating disease. The development of anti-CD40L for the treatment of autoimmune diseases offers a unique opportunity to silence disease progression and offer long-term remission.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2022 | 2 | NIH | $1,965,799 | |
| Project Title: Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | ||||
| 2020 | 2 | NIH | $3,287,234 | |
| Project Title: Targeting Leukocyte Metabolism to Treat Human Autoimmune Disease | ||||
| 2019 | 2 | NIH | $3,288,345 | |
| Project Title: Targeting the Checkpoint Regulator Vista for Treatment of Inflammatory Disease | ||||
| 2015 | 2 | NIH | $2,549,257 | |
| Project Title: Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease | ||||
| 2013 | 1 | NIH | $290,914 | |
| Project Title: Safe and Effective Anti-Cd154 Antibodies for Therapeutic Intervention | ||||
Key People / Management
David DeLucia -- Chief Executive Officer
Matthew F Mackey
Randolph Noelle -- Chief Scientific Officer
Michael Rosenzweig -- Vice President of Research and Development
Jay L Rothstein -- Vice President of Research and Development
Matthew F Mackey
Randolph Noelle -- Chief Scientific Officer
Michael Rosenzweig -- Vice President of Research and Development
Jay L Rothstein -- Vice President of Research and Development
